Moreover, statin potentiation appeared selective for APis as no potentiation was observed for two types of other drugs: CHR2875, an HDAC inhibitor prodrug[35], which is bioactivated similarly as CHR2863, and daunorubicin evaluated in combination chemotherapy with Tosedostat for AML [Figure 3 and Supplementary Figure 1]. Here, HDAC9 is linked to acute myeloid leukemia.